Pharma channel feed

Is the $74B Cel­gene buy­out al­ready forc­ing a reck­on­ing among Bris­tol-My­ers Squibb’s R&D part­ners?

7 years ago
Deals

Ad­di­tion­al ex­clu­siv­i­ty for a can­cer treat­ment could cost the pub­lic $3 bil­lion, an­a­lyst says

7 years ago

FDA sounds the alarm on Pfiz­er’s block­buster Xel­janz af­ter a high dose was linked to a high­er death rate, blood clots

7 years ago
R&D

Dana­her hands a dis­tressed GE $21B+ for bio­phar­ma busi­ness that made $3B last year

7 years ago

By the num­bers: Top M&A deals, VC in­vest­ments and pacts point to a grow­ing hunger for gene ther­a­py deals

7 years ago
Cell/Gene Tx

Un­fazed by re­cent car­dio set­backs, No­var­tis takes an­oth­er PhI­II chal­lenge head-on with Akcea drug

7 years ago

Karyopharm shares tank af­ter FDA in­sid­ers slam their case on the ef­fi­ca­cy of a can­cer drug with “sig­nif­i­cant tox­i­c­i­ty”

7 years ago
R&D

Ab­b­Vie hands Voy­ager a mega-bil­lions gene ther­a­py deal, with $310M in near-term cash

7 years ago
R&D

EMA opens con­sul­ta­tion on guide­line for ad­vanced ther­a­pies in clin­i­cal tri­als

7 years ago

Bio­Marin CEO JJ Bi­en­aimé is plan­ning for a block­buster fu­ture in the gene ther­a­py biz: to the tune of $10B to $15B a year

7 years ago

Two years fol­low­ing US ap­proval, Japan's Sh­iono­gi wins EU green light for opi­oid con­sti­pa­tion drug

7 years ago

So you just got a BTD for your top drug? Don't be sur­prised to see the en­thu­si­asm fiz­zle fast among in­vestors

7 years ago

Dear Bernie: Cat­a­lyst CEO McE­nany de­fends his $375,000 price tag on an old drug once of­fered for free

7 years ago

J&J steps up along­side Ab­b­Vie to part­ner with fast-grow­ing Mor­phic on its small mol­e­cule ap­proach to in­te­grins

7 years ago
R&D

FDA cites an ‘on­go­ing re­view’ for Pfiz­er's block­buster Xel­janz, with im­pli­ca­tions for the class

7 years ago

IP trou­ble de­fers launch of Novo's long-act­ing he­mo­phil­ia ther­a­py

7 years ago

Stem cell ther­a­pies for space mis­sions? Pluris­tem joins forces with NASA to com­bat space-re­lat­ed ail­ments

7 years ago
R&D
Cell/Gene Tx

FDA cau­tions over young donor blood trans­fu­sions to treat ag­ing, mem­o­ry loss

7 years ago

As gener­ic com­pe­ti­tion stut­ter sales of top on­col­o­gy drugs, Roche se­cures speedy re­view for pair of ex­per­i­men­tal can­cer of­fer­ings

7 years ago

Trop­i­cal dis­ease PRV fix didn’t stop No­var­tis from win­ning an­oth­er

7 years ago

FDA doc re­veals agency charged Im­munomedics with da­ta in­tegri­ty breach af­ter Au­gust plant in­spec­tion

7 years ago

Ap­pro­pri­a­tions bill would give FDA $269M boost over FY2018 bud­get

7 years ago

Ra­maswamy's Ax­o­vant whips up a CNS spin­off with a $530M deal and a syn­di­cate of sup­port­ers

7 years ago
Startups

DBV es­ti­mates peanut al­ler­gy drug sub­mis­sion in Q3, but it may be too lit­tle too late in race with Aim­mune

7 years ago
First page Previous page 275276277278279280281 Next page Last page
A service from the Financial Times